LBLing Bi

Ling Bi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling Bi has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Shi

    Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No.110, Ganhe Road, Hongkou District, Shanghai, 200437 China

    1 shared publication
  • Lijing Jiao

    Institute of Traditional Chinese Medicine Oncology, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication
  • Ling Xu

    Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, P.R. China

    1 shared publication
  • Qin Wang

    Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China

    1 shared publication
  • Yabin Gong

    Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    1 shared publication
  • Yan Lu

    Department of Cancer Center, Yueyang Hospital of integrated traditional Chinese and western medicine, Shanghai university of traditional Chinese medicine, 110 Ganhe Road, Shanghai, 200437, PR China

    1 shared publication

Latest Publications

  • Open Access

    Cancer chemoprevention and therapy using chinese herbal medicine

    by Lijing Jiao, Ling Bi, Yan Lu, Qin Wang, Yabin Gong, Jun Shi, Ling Xu

    Traditional Chinese medicine (TCM) plays an indispensable role in cancer prevention and treatment. Chinese herbal medicine (CHM) is a key component of TCM and has been practiced for thousands of years. A number of naturally occurring products from Chinese herbs extracts exhibit strong inhibitory properties against carcinogenesis, including CHM single-herb extracts, CHM-derived active components, and CHM formulas (the polyherbal combinations), which regulate JAK/STAT, MAPK, and NF-ҡB pathways. The present review aims to report the cancer-preventive effect of CHM with evidence from cell-line, animal, epidemiological, and clinical experiments. We also present several issues that have yet to be resolved. In the future, cancer prevention by CHM will face unprecedented opportunities and challenges.